Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool February 29, 2008 Brian Orelli	Bigger Recall, No Big Deal Baxter increases its recall of heparin, but investors shouldn't be that worried.
The Motley Fool April 18, 2008 Brian Orelli	Recalls Can't Beat Baxter In spite of charges for two recalls, Baxter posts a decent quarter.
The Motley Fool April 2, 2008 Brian Lawler	Medicines Company Sets Itself Apart Drugmaker Medicines Company wants to distance its angioplasty treatment from heparin.
The Motley Fool February 21, 2008 Brian Lawler	A Bit of Irony From the FDA The agency has a mixed message on drug importation, as evidenced in the recent possible contamination of China-produced Heparin.
Fast Company April 2004 Keith H. Hammonds	Moment of Truth? It has been a tortuous year for Harry M. Jansen Kraemer Jr., CEO of Baxter International Inc. Back in November 2002, we lauded Kraemer's forthright leadership as his company confronted the deaths of 53 patients due to contaminated dialysis filters made by a Baxter subsidiary. Now Kraemer is out of a job.
Chemistry World August 19, 2008 Ananyo Bhattacharya	Flask synthesis promises untainted heparin US researchers have created milligrams of pure heparin using enzymes and chemicals - a practical laboratory synthesis that could avoid the contamination issues surrounding the blood-thinning drug
The Motley Fool March 10, 2008 Brian Orelli	Breakup Weighs Down APP It's going to take awhile for APP Pharmaceuticals to reward investors.
The Motley Fool March 7, 2008 Brian Lawler	A Little Too Much Drug Variability Another drugmaker has to recall batches of its compound.
The Motley Fool July 20, 2007 Brian Orelli	Baxter's Mixed Message A recall of Baxter BioScience's COLLEAGUE infusion pumps seems to have over-shadowed healthy quarterly earnings reports.
The Motley Fool August 26, 2008 Brian Orelli	Baxter Ready to Sop Up Additional Revenue The health-care giant licenses a surgical sponge in clinical development.
Chemistry World August 7, 2015 Suzanne Howson	Simple probe for heparin quality control Scientists in China have developed a fluorescent probe to detect both heparin and its major contaminant. The sensor could make it easier to monitor the quality of heparin supplies.
Fast Company November 2002 Keith H. Hammonds	Harry Kraemer's Moment of Truth In an era when the business section read like the police blotter, the CEO of medical products and pharmaceutical company Baxter International faced a tough ethical dilemma. And he did something noteworthy: He actually did the right thing.
The Motley Fool September 24, 2008 Brian Orelli	Hey, You! Stop! The FDA has ordered Baxter and Hospira to stop making their ophthalmic balanced salt solutions within 60 days.
Chemistry World April 20, 2011 Jon Cartwright	New clotting drug antidote could cut surgery risk Chemists in the UK have developed a possible alternative to protamine, a molecule used by doctors to counteract the effects of anti-clotting drugs.
The Motley Fool April 20, 2006 Stephen D. Simpson	Baxter Bags Better Margins This is a great business -- but only at the right price. Investors, this story has to be bought cheap. At today's prices, is it cheap enough?
The Motley Fool March 31, 2008 Brian Lawler	FDA Commish Joins Blogosphere Andrew von Eschenbach, the FDA's chief, starts a weekly blog.
Chemistry World November 23, 2009 Phil Taylor	Pharma group aims to banish contaminated ingredients An international consortium aiming to tighten security in the pharmaceutical supply chain and avoid contaminated ingredients finding their way into medicines had its European debut this month.
The Motley Fool October 19, 2007 Brian Orelli	Baxter Gets Pumped Up Medical-device maker Baxter puts in a nice quarter despite two recent FDA recalls.
The Motley Fool December 23, 2003 Jeff Hwang	Bad, Bad Baxter The medical products company issues its latest in a series of earnings warnings.
The Motley Fool September 27, 2007 Billy Fisher	Baxter Looking to Bounce Back Shares of the medical device maker finally rebound following a company recall of infusion pumps.
The Motley Fool November 3, 2011 Dan Caplinger	Has Baxter International Become the Perfect Stock? Baxter needs to keep working on getting its debt levels down and seek out new growth opportunities. With favorable demographic winds at its back, Baxter could be the rare stock to actually reach perfection.
Chemistry World February 12, 2014 Amy Middleton-Gear	Neutralizing heparin without complications Recovering from operations could become easier thanks to a self-assembling multivalent heparin binding agent being developed by scientists in the UK, Italy and Spain.
The Motley Fool April 17, 2009 Robert Steyer	The Steady BAX Beat Baxter International's diverse medical offerings continue to produce prosperity.
The Motley Fool January 23, 2009 Robert Steyer	BAX to the Future After minding its own business, Baxter International starts thinking about acquisitions again.
The Motley Fool April 22, 2005 Brian Gorman	Baxter Is on the Mend The medical products company continues to right itself for a brighter future. The firm's long-term positioning and diversified business may make it worth a closer look.
The Motley Fool January 28, 2005 Brian Gorman	Baxter Plods On 2005 looks like another year of transition for Baxter International. The medical products and services concern reported that after currency adjustments, fourth-quarter 2004 revenue of $2.6 billion was essentially flat compared with the same period in 2003.
The Motley Fool February 26, 2009 Brian Orelli	Ranbaxy Spoils It for Everyone The Food and Drug Administration claims that generic-drug maker Ranbaxy falsified data that it submitted to the agency. Other innocent drug companies may suffer from guilt by association.
Chemistry World June 21, 2010 Sarah Houlton	Recalling pharma Recent drug withdrawals and manufacturing failures have highlighted the importance of ensuring that the medicines patients take contain what it says on the label.
Registered Rep. June 14, 2007 Kevin Burke	Pilgrim Baxter's Payback The SEC announced this week that it is returning ill-gotten gains to Pilgrim Baxter (investment advisor to the PBHG fund family) shareholders, three and half years after the fund company was engulfed in a trading scandal.
The Motley Fool January 25, 2008 Brian Orelli	Where the Big Margins Are Drug company investors get to enjoy such high gross margins, but there's generally only so much improvement that a company can make when it starts from such a high point. Take a look at some pharma companies that are succeeding to do just that.
Chemistry World March 28, 2014 Phillip Broadwith	Baxter aims to divide and conquer US drugmaker Baxter International is spinning off its biopharmaceuticals business to create two independent companies.